文献速递新发突发、热带与寄生虫病

登革热四价减毒活疫苗在4型免疫个体中被抑制

A Live Attenuated Dengue Virus Vaccine (Dengvaxia) is Suppressed in Individuals with Immunity to Serotype 4.
PubMed 文献 · J Infect Dis · 2026-10-28

该前瞻性队列研究在菲律宾2016年儿童接种Dengvaxia时建立,评估基线登革热血清状态对疫苗应答的影响。结果显示基线DENV1、2或3型免疫儿童产生交叉中和抗体应答,而DENV4单型免疫儿童中疫苗抑制频率达61%。结论证实疫苗中DENV4组分复制优势,且预存DENV4免疫直接抑制疫苗。

要点

  • 基线DENV1-3免疫儿童接种后产生交叉中和抗体应答,支持疫苗在血清阳性儿童中的良好表现。
  • 基线DENV4单型免疫儿童中61%出现疫苗抑制,提示预存DENV4免疫抑制疫苗复制。
  • Dengvaxia在人体内实际表现类似单价DENV4疫苗,因DENV4疫苗病毒复制优于其他血清型。

核心结论

  • Dengvaxia中DENV4疫苗组分复制占优势,预存DENV4免疫直接导致疫苗抑制。
  • 基线DENV1、2或3型免疫儿童接种后产生交叉中和抗体应答,可能解释血清阳性儿童中的良好效果。

研究设计与样本

  • 2016年菲律宾儿童接种Dengvaxia时建立前瞻性队列,按基线登革热血清状态评估疫苗表现。
  • 本文报告基线各血清型单型免疫对Dengvaxia应答的影响。

主要发现

  • 基线DENV1、2或3型免疫儿童中,疫苗刺激产生继发性血清型交叉中和抗体应答。
  • 基线DENV4单型免疫儿童中,疫苗抑制频率高达61%。

临床怎么用

  • 评估登革热疫苗在血清阳性个体中的表现时,需考虑基线各血清型免疫状态。
  • Dengvaxia在DENV4单型免疫儿童中可能被抑制,接种前应关注基线血清型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dengvaxia® was the first live attenuated tetravalent dengue virus (DENV) vaccine to be tested and approved for use in people. While Dengvaxia was designed to be tetravalent, in humans, the vaccine performed like a monovalent DENV4 vaccine because the DENV4 vaccine virus replicated better than other vaccine serotypes. Dengvaxia® was safe and efficacious in children who were DENV-immune at baseline and contraindicated for use in DENV-naïve children. METHODS: When Dengvaxia® was rolled out as a pediatric vaccine in the Philippines in 2016, we established a prospective cohort to assess vaccine performance by baseline dengue serostatus. Here we report on how baseline monotypic immunity to each serotype (reflecting one past DENV infection) impacted Dengvaxia® responses. RESULTS: We observed that in children with baseline immunity to DENV1, 2 or 3, the vaccine stimulated a secondary serotype cross-neutralizing Ab response, which likely explains the overall favorable performance of the vaccine in seropositive children enrolled in phase 3 trials. We observed a high frequency (61%) of vaccine suppression among DENV4 monotypic immune children. CONCLUSIONS: Our results confirm the replication dominance of the DENV4 vaccine component in Dengvaxia® and directly implicate pre-existing DENV4 immunity in the suppression of the vaccine. Our results have broader implications for evaluating the performance of other DENV vaccines in seropositive individuals.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Adams C, Hein LD, White LJ, et al. A Live Attenuated Dengue Virus Vaccine (Dengvaxia) is Suppressed in Individuals with Immunity to Serotype 4. J Infect Dis. 2026. PMID: 42947633. doi:10.1093/infdis/jiag522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。